Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03599635 · ClinicalTrials.gov registry record · Phase 4

Pec Infiltration With Liposomal Bupivacaine for Breast Surgery

A Phase 4 study, sponsored by University of Minnesota.

Completed
Registry status
Phase 4
Development phase
112
Enrollment target

NCT03599635: Completed Phase 4 study, sponsored by University of Minnesota.

NCT03599635 is a Phase 4 study that has completed, run by University of Minnesota. The registered enrollment target is 112 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03599635, a Phase 4 study, has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
Phase 4
Development phase
112 participants
Enrollment target

Study Summary

The purpose of this study is to compare pain control after breast surgery using either liposomal bupivacaine or bupivacaine when infiltrated during an ultrasound guided pectoralis 1 and 2 block. Both medications, liposomal bupivacaine and bupivacaine, are standard of care in these types of surgeries.

Primary Outcome

Description: To determine if liposomal bupivacaine Pec infiltration provides decreased peri-operative opioid usage when compared to incisional bupivacaine infiltration.

Interventions

  • DRUG Bupivacaine
  • DRUG liposomal bupivacaine

Trial Details

FieldValue
Enrollment Target 112 participants
Start Date 2018-07-01
Est. Completion 2024-07-01
Phase Phase 4
University of Minnesota

966 total trials

What the finished NCT03599635 record still lists

NCT03599635 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.

NCT03599635 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03599635 about?

NCT03599635 is a clinical study titled "Pec Infiltration With Liposomal Bupivacaine for Breast Surgery". The purpose of this study is to compare pain control after breast surgery using either liposomal bupivacaine or bupivacaine when infiltrated during an ultrasound guided pectoralis 1 and 2 block. Both medications, liposomal bupivacaine and bupivacaine, are standard of care in these types of surgeries...

What is the current status of trial NCT03599635?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 112 participants. The study started on 2018-07-01. Estimated completion is 2024-07-01.

What interventions are being tested in trial NCT03599635?

The interventions under investigation include: Bupivacaine (DRUG), liposomal bupivacaine (DRUG).

Who is sponsoring clinical trial NCT03599635?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03599635's enrollment target sits among peer trials

112 724th of 2000 higher than 1,275 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04511013 · 112 participants · Phase 2

    A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

  • NCT04551560 · 112 participants · NA

    Stress and Congestive Heart Failure

  • NCT04872166 · 112 participants · Phase 1

    A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

  • NCT05024773 · 112 participants · Phase 3

    Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03599635, the US trial registry maintained by the National Library of Medicine. NCT03599635 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.